The Hidden Language Of RNA: How lncRNA-Splicing Networks Are Redefining The Future Of Therapeutics

By Pushkar Malakar, Ph.D., assistant professor, Ramakrishna Mission Vivekananda Educational and Research Institute

For decades, biology operated under a relatively straightforward paradigm: DNA encoded RNA, RNA encoded proteins, and proteins carried out the functions that determined health and disease. Drug discovery followed suit. The vast majority of therapeutics developed over the past century have been designed to modulate proteins, whether through inhibition, activation, degradation, or replacement.

Yet as our understanding of the human genome has deepened, it has become increasingly apparent that proteins tell only part of the story.

While protein-coding genes account for less than 2% of the human genome, much of the remaining genomic landscape is actively transcribed into RNA molecules that do not encode proteins at all. For many years these transcripts were dismissed as transcriptional noise or evolutionary remnants. Today, they are emerging as some of the most important regulators of cellular behavior.

Among these molecules, long non-coding RNAs (lncRNAs) have attracted particular attention. These transcripts, typically longer than 200 nucleotides, participate in the control of gene expression, chromatin organization, cellular differentiation, and disease progression. Increasingly, evidence suggests that their influence is often exerted through an equally important biological process: alternative splicing.

Together, lncRNAs and splicing factors form complex regulatory networks that determine how genetic information is interpreted inside cells. These networks influence not only which genes are expressed but also which versions of those genes ultimately become functional products. Understanding this hidden layer of biology may prove critical to the future of RNA therapeutics.

Beyond Gene Expression

When discussing RNA biology, much attention is often given to gene expression. Researchers frequently measure whether a gene is turned on or off, and whether transcript levels increase or decrease under specific conditions.

However, expression alone rarely captures the full complexity of cellular regulation.

A single gene can generate multiple messenger RNA isoforms through alternative splicing, a process that selectively includes or excludes specific exons during RNA processing. The resulting transcripts may produce proteins with dramatically different functions, localization patterns, or biological activities.

Alternative splicing is not a rare exception to the rule. It is a defining feature of eukaryotic biology.

More than 95% of multi-exon human genes undergo alternative splicing, allowing a relatively limited number of genes to generate enormous functional diversity. In many cases, disease arises not because a gene is absent or mutated but because the wrong splice variant is produced.

Cancer, neurodegenerative disorders, cardiovascular disease, and fibrosis have all been linked to aberrant splicing programs. The question, therefore, is not simply which genes are expressed. It is how cells decide which versions of those genes should exist. Increasingly, lncRNAs appear to play a central role in that decision-making process.

lncRNAs As Architects Of Cellular Identity

Unlike messenger RNAs, lncRNAs rarely function as passive intermediates between DNA and proteins. Instead, they often serve as molecular organizers that coordinate interactions among proteins, RNA molecules, and genomic regions.

Some lncRNAs act as scaffolds, bringing together multiple regulatory proteins. Others function as guides, directing transcription factors or chromatin modifiers to specific genomic loci. Still others serve as decoys that sequester proteins away from their normal targets.

One of the most intriguing aspects of lncRNA biology is their ability to influence splicing machinery directly.

Splicing factors must operate with extraordinary precision. They identify exon-intron boundaries, coordinate spliceosome assembly, and determine which transcript variants ultimately emerge from precursor RNAs. Small disruptions in these processes can have profound biological consequences.

Research increasingly demonstrates that lncRNAs participate in regulating splicing factor recruitment, activity, localization, and target selection. In doing so, they exert influence over entire gene expression programs rather than individual molecular events.

This systems-level control makes lncRNAs particularly attractive therapeutic targets. Rather than targeting a single downstream protein, modulating a disease-associated lncRNA may allow intervention at a higher regulatory level, influencing multiple disease-driving pathways simultaneously.

The Convergence Of RNA Therapeutics And Regulatory Biology

The rapid rise of RNA therapeutics has transformed what is possible in drug development.

The clinical success of antisense oligonucleotides, siRNA medicines, and mRNA platforms has demonstrated that RNA is not merely a target but also a therapeutic modality in its own right. These advances have enabled the field to move beyond the longstanding question of whether RNA medicines can work. The focus is now shifting toward identifying the most impactful biological targets.

This transition is particularly relevant for lncRNAs and splicing networks.

Historically, many diseases were approached through a protein-centric lens. Researchers searched for enzymes, receptors, or signaling molecules that could be manipulated using conventional small molecules or biologics.

However, many disease-driving processes occur upstream of proteins. Cell-state transitions, developmental programs, fibrosis, inflammation, and tumor progression are often governed by regulatory networks that are difficult to access through traditional pharmacology. lncRNAs occupy a unique position within these networks. Because they frequently influence chromatin architecture, transcriptional regulation, and RNA processing simultaneously, they provide opportunities to reshape disease biology at its source rather than merely addressing downstream consequences.

Alternative Splicing As A Therapeutic Opportunity

The therapeutic relevance of alternative splicing is already well established.

Several approved RNA medicines function by modifying splicing outcomes. These successes have validated the concept that splicing is not only biologically important but also therapeutically actionable. Yet we are still in the early stages of understanding how splicing programs are controlled at a systems level.

Many current approaches focus on correcting individual splicing events associated with specific diseases. While effective in certain contexts, this strategy addresses only a fraction of the broader regulatory landscape.

Future therapeutic opportunities may emerge from understanding the upstream networks that coordinate multiple splicing decisions simultaneously. lncRNAs represent one of the most promising entry points into these networks.

By influencing the activity of splicing factors, lncRNAs can affect numerous transcripts across interconnected biological pathways. This creates the possibility of achieving broader therapeutic effects through highly selective interventions. The challenge, of course, lies in identifying which lncRNAs are truly causal drivers rather than passive bystanders.

From Correlation To Function

One of the most significant obstacles facing regulatory RNA therapeutics today is functional validation.

Advances in sequencing technologies have generated vast catalogs of non-coding RNAs associated with disease. However, association does not establish causation.

Many lncRNAs exhibit altered expression in disease states, but determining which molecules actively contribute to pathology remains difficult. This is where mechanistic biology becomes essential.

Researchers increasingly rely on technologies that map RNA-protein interactions, chromatin associations, and regulatory networks. These approaches help reveal how lncRNAs influence cellular behavior and which molecular partnerships are responsible for disease-related functions.

Understanding these interactions is critical for therapeutic development. A successful RNA medicine requires more than target identification. It requires confidence that modulating a target will produce predictable biological outcomes. As regulatory RNA programs advance toward the clinic, functional characterization will become an increasingly important competitive differentiator.

The Emergence Of Cell-State Therapeutics

Perhaps the most exciting implication of lncRNA-splicing biology is its connection to cell-state control.

Many diseases are increasingly understood as disorders of cellular identity rather than isolated molecular defects. Fibrotic fibroblasts, exhausted immune cells, malignant cancer cells, and dysfunctional metabolic tissues often arise because normal regulatory programs have been disrupted. Once established, these pathological states can become self-reinforcing.

Traditional therapeutics frequently attempt to block individual disease pathways without fundamentally altering the underlying cellular state. Regulatory RNAs offer a different possibility.

Because they operate at the level of gene networks and transcriptional programs, lncRNAs may enable therapeutic reprogramming of diseased cells. Rather than inhibiting a single downstream target, future therapies could potentially restore healthier cellular behaviors by resetting regulatory circuits.

This concept remains in its early stages, but it represents one of the most compelling directions in modern drug discovery.

Challenges Ahead

Despite growing enthusiasm, significant challenges remain.

The biological complexity of lncRNAs can complicate target validation and therapeutic development. Many lncRNAs exhibit tissue-specific expression patterns, context-dependent functions, and limited evolutionary conservation.

Delivery remains another important consideration. Although substantial progress has been made in RNA delivery technologies, many regulatory RNA targets reside in tissues that remain difficult to access efficiently.

Manufacturing, regulatory considerations, and biomarker development also continue to evolve as the field matures. Nevertheless, these challenges increasingly resemble engineering problems rather than fundamental scientific barriers.

The field has already demonstrated that RNA can be delivered, modified, manufactured, and commercialized successfully. The next phase will focus on identifying the most valuable biological opportunities.

Looking Forward

The history of drug discovery has largely been a history of proteins. That history is not ending. Proteins will remain essential therapeutic targets for decades to come.

What is changing is our understanding of the biological systems that govern protein function. lncRNAs, alternative splicing networks, and other regulatory RNA mechanisms reveal a layer of biology that was largely invisible to previous generations of researchers. These systems help determine how genes are interpreted, how cellular identities are maintained, and how diseases emerge.

As RNA therapeutics continue to evolve, the most transformative opportunities may come not from replacing proteins or silencing genes but from controlling the regulatory networks that orchestrate cellular behavior itself. The future of RNA medicine may therefore depend on learning to speak a language that biology has been using all along — a language written not only in genes and proteins but in the intricate conversations between non-coding RNAs, splicing factors, and the regulatory programs that define life.

About The Author:

Pushkar Malakar, Ph.D., is a Ramanujan Fellow and assistant professor in the Department of Medical Biotechnology at the School of Biological Sciences, Ramakrishna Mission Vivekananda Educational and Research Institute (RKMVERI). His research focuses on the role of long non-coding RNAs, alternative splicing, cancer metabolism, chromosomal instability, and RNA-mediated regulatory mechanisms in human disease. Prior to joining RKMVERI, Malakar completed postdoctoral training at the Hebrew University of Jerusalem and the National Cancer Institute at the U.S. National Institutes of Health (NIH). He has authored numerous peer-reviewed publications on lncRNA biology, cancer progression, and RNA regulation, with a particular interest in translating fundamental discoveries in RNA biology into future therapeutic opportunities.